Breaking News Instant updates and real-time market news.

BGNE

BeiGene

$113.91

-3.57 (-3.04%)

07:17
06/18/19
06/18
07:17
06/18/19
07:17

BeiGene, SpringWorks Therapeutics form MapKure to develop BGB-3245

BeiGene and SpringWorks Therapeutics announced the formation of MapKure, a newly created entity that is jointly owned by BeiGene and SpringWorks. MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions. These mutations and fusions have been identified in a number of solid tumors to be drivers of cancer growth, including in non-small cell lung cancer, colorectal cancer, thyroid cancer, and brain tumors. BGB-3245 was discovered by BeiGene scientists and is currently in preclinical development. Under the terms of the agreements, SpringWorks has made an equity investment into MapKure and BeiGene has contributed an exclusive royalty and milestone-bearing license to develop and commercialize BGB-3245 outside of Asia, but including rights to Japan, in exchange for a majority ownership position in MapKure. MapKure will form a joint steering committee that will oversee clinical development and operations for BGB-3245, as well as a Board of Directors. Both the joint steering committee and the Board will include members from BeiGene, SpringWorks and MapKure's CEO. Further terms of the agreements were not disclosed. Neal Rosen, M.D., Ph.D., Director of the Center for Mechanism-Based Therapeutics and the incumbent of the Enid A. Haupt Chair in Medical Oncology at Memorial Sloan-Kettering Cancer Center, is the founding member of the MapKure Scientific Advisory Board. BeiGene and SpringWorks plan for MapKure to initiate an adaptive Phase 1 dose-escalation and expansion study of BGB-3245 in solid tumor patients harboring specific B-RAF driver mutations and RAF fusions, as well as in patients who have developed resistance to first-generation BRAF inhibitors. MapKure intends to enter into service agreements with both BeiGene and SpringWorks to enable the execution of this study and to perform other activities to support MapKure operations. Subsequent clinical development efforts with BGB-3245 may also include rational combination therapies, including with MEK inhibitors such as PD-0325901, which is being developed by SpringWorks. Lusong Luo, Ph.D., Senior Vice President of External Innovation at BeiGene, will be Acting CEO of MapKure and a member of the MapKure Board of Directors.

  • 20

    Jun

BGNE BeiGene
$113.91

-3.57 (-3.04%)

05/09/19
PIPR
05/09/19
NO CHANGE
Target $180
PIPR
Overweight
BeiGene price target raised to $180 from $170 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target on BeiGene to $180 and kept his Overweight rating after its Q1 results showing sales of Abraxane, Revlimid, and Vidaza in China experiencing a "very nice" sequential rebound after flat performance in Q4. The analyst is also positive on the company's growth driven by increased reimbursement coverage and the Revlimid label expansion in newly-diagnosed patients, as well as its prospects from the three applications that are currently undergoing priority review in China, with "potential approvals and launches coming soon."
05/10/19
LYON
05/10/19
UPGRADE
LYON
Buy
BeiGene upgraded to Buy from Outperform at CLSA
05/10/19
LYON
05/10/19
UPGRADE
LYON
Buy
BeiGene upgraded to Buy ahead of expected Chinese approvals at CLSA
As previously reported, CLSA upgraded BeiGene to Buy from Outperform as they see manufacturing approval of two drug candidates - Zanubrutinib and Tislelizumab - in China as the next catalyst for the shares. The firm keeps a HK$96.52 price target on BeiGene shares.
06/04/19
BERN
06/04/19
INITIATION
Target $201
BERN
Outperform
BeiGene initiated with an Outperform at Bernstein
Bernstein started BeiGene with an Outperform rating and $201 price target.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$114.02

-1.3 (-1.13%)

, JNJ

Johnson & Johnson

$134.89

0.6 (0.45%)

14:53
07/15/19
07/15
14:53
07/15/19
14:53
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JPM

JPMorgan

$114.02

-1.3 (-1.13%)

JNJ

Johnson & Johnson

$134.89

0.6 (0.45%)

WFC

Wells Fargo

$46.66

-0.69 (-1.46%)

GS

Goldman Sachs

$211.67

-2.28 (-1.07%)

PLD

Prologis

$80.11

0.08 (0.10%)

FRC

First Republic

$98.89

-1.74 (-1.73%)

DPZ

Domino's Pizza

$269.81

-12.42 (-4.40%)

SNV

Synovus

$34.65

-0.78 (-2.20%)

FHN

First Horizon

$14.89

-0.22 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 29

    Jul

  • 30

    Jul

  • 06

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 12

    Oct

  • 13

    Nov

JBHT

J.B. Hunt

$92.62

-0.33 (-0.36%)

14:52
07/15/19
07/15
14:52
07/15/19
14:52
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

JBHT

J.B. Hunt

$92.62

-0.33 (-0.36%)

14:49
07/15/19
07/15
14:49
07/15/19
14:49
Options
J B Hunt Transport Services options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

AGRX

Agile Therapeutics

$1.30

0.01 (0.78%)

14:48
07/15/19
07/15
14:48
07/15/19
14:48
Recommendations
Agile Therapeutics analyst commentary  »

FDA guidance looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$41.82

0.575 (1.39%)

14:45
07/15/19
07/15
14:45
07/15/19
14:45
Options
Taiwan Semi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ALTR

Altair

$41.54

0.37 (0.90%)

14:37
07/15/19
07/15
14:37
07/15/19
14:37
Hot Stocks
Altair beneficial owner George Christ sells $1.5M in company shares »

Altair beneficial owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$211.82

-2.13 (-1.00%)

, BAC

Bank of America

$29.19

-0.25 (-0.85%)

14:36
07/15/19
07/15
14:36
07/15/19
14:36
Earnings
Fly Intel: What to watch in next round of big banks' earnings reports »

Goldman Sachs (GS), Bank…

GS

Goldman Sachs

$211.82

-2.13 (-1.00%)

BAC

Bank of America

$29.19

-0.25 (-0.85%)

MS

Morgan Stanley

$44.60

-0.27 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 06

    Aug

  • 06

    Sep

AMBA

Ambarella

$46.20

-0.06 (-0.13%)

14:35
07/15/19
07/15
14:35
07/15/19
14:35
Options
Ambarella put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

, SPX

S&P 500

$0.00

(0.00%)

14:29
07/15/19
07/15
14:29
07/15/19
14:29
General news
Mnuchin said he thinks a budget deal is 'close' »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

, SPX

S&P 500

$0.00

(0.00%)

14:27
07/15/19
07/15
14:27
07/15/19
14:27
General news
Mnuchin says had 'very productive' talks with Pelosi on debt ceiling »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$12.55

0.41 (3.38%)

14:26
07/15/19
07/15
14:26
07/15/19
14:26
Conference/Events
LogicBio Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

QURE

uniQure

$68.66

-1.74 (-2.47%)

14:25
07/15/19
07/15
14:25
07/15/19
14:25
Options
uniQure call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

AVGO

Broadcom

$290.65

5.26 (1.84%)

, SYMC

Symantec

$21.78

-3.78 (-14.79%)

14:21
07/15/19
07/15
14:21
07/15/19
14:21
Periodicals
Broadcom still keen to find solution as Symantec bid stalls over price, FT says »

Broadcom's (AVGO)…

AVGO

Broadcom

$290.65

5.26 (1.84%)

SYMC

Symantec

$21.78

-3.78 (-14.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/15/19
07/15
14:17
07/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/15/19
07/15
14:16
07/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$26.49

-0.32 (-1.19%)

14:15
07/15/19
07/15
14:15
07/15/19
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

14:15
07/15/19
07/15
14:15
07/15/19
14:15
General news
Fed funds futures are fractionally higher »

Fed funds futures are…

FB

Facebook

$203.96

-0.945 (-0.46%)

, BTC

Bitcoin

$0.00

(0.00%)

14:14
07/15/19
07/15
14:14
07/15/19
14:14
Hot Stocks
Mnuchin says Trump has cryptocurrency concerns, won't target a specific provider »

Asked about President…

FB

Facebook

$203.96

-0.945 (-0.46%)

BTC

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

C

Citi

$71.87

0.12 (0.17%)

14:11
07/15/19
07/15
14:11
07/15/19
14:11
Hot Stocks
Citi reports June credit loss rate 2.56% vs. 2.74% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 13

    Aug

FB

Facebook

$203.77

-1.135 (-0.55%)

14:09
07/15/19
07/15
14:09
07/15/19
14:09
Hot Stocks
Breaking Hot Stocks news story on Facebook »

Mnuchin says Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

FB

Facebook

$203.81

-1.095 (-0.53%)

, BTC

Bitcoin

$0.00

(0.00%)

14:07
07/15/19
07/15
14:07
07/15/19
14:07
Hot Stocks
Mnuchin says Treasury has 'serious concerns' about Facebook's Libra, bitcoin »

Treasury Secretary Steven…

FB

Facebook

$203.81

-1.095 (-0.53%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Options
Charles Schwab call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

CSGP

CoStar Group

$583.45

-3.56 (-0.61%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Hot Stocks
CoStar Group signs agreement with Behar Group Realty »

CoStar Group is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 12

    Aug

  • 13

    Nov

HTGC

Hercules Capital

$12.96

-0.02 (-0.15%)

14:00
07/15/19
07/15
14:00
07/15/19
14:00
Hot Stocks
Hercules Capital reports separation agreement with Manuel Henriquez »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GLPG

Galapagos

$170.88

25.21 (17.31%)

13:59
07/15/19
07/15
13:59
07/15/19
13:59
Downgrade
Galapagos rating change at Raymond James »

Galapagos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.